Latest Stock Buy or Sell? Make More Informed Decisions!

Today, Hap (Robert) Sneddon FCSI commented about whether PBH.TO, IBB, XGD.TO, CNR.TO, NVDA, ARX.TO, ING, BPY.UN.TO, K.TO, NFI.TO, ERF.TO, FTS.TO, ZRE.TO, TECK.B.TO, NEM, CTC.A.TO, GIB.A.TO, CM.TO, TOY.TO are stocks to buy or sell.

COMMENT

It ran into congestion last summer between $24-28, and is in the same range this year. $24 is key; if it falls below $24, it'll plunge to $20. If you want safety, look at the XRE-T instead.

HOLD
It bottomed last December at $10.21 and has now made a higher low, which is a good sign. If it rises above $13, it will see momentum, which has been lacking for quite a while. If it can rise above $13, it will signal momentum, which has been lacking lately. That breakout means it will reach $16 easily. Hold onto it.
DON'T BUY
It's in no-man's land now. Avoid new lows like this. This could fall to $5.
BUY
It made a low in December with a higher low in Februay. First resistance will be at $160, then at $182. If it breaks that, it will challenge its old $300 high. It participated in today's rally which is a good sign.
HOLD

He owns CP, which has a better profile. Don't sell CNR, but hold.

TOP PICK
He's very bullish gold. Good risk/reward for the next three months. He's recommended gold stocks elsewhere on this show, but this is a good basket of them.
TOP PICK
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
TOP PICK

Hit a high of $120 in Febuary 2018 and fell to $75 in December. It's now breaking resitance at $84. They just reported a 33% increase in EBITDA, and 40% increase in earnings. EPS is slightly down due to acquisitions. Estimates for this year are 24% and 48% higher next year. The Canadian Pension Board just invested in this. (Analysts’ price target is $90.73)